Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. reported March 31, 2026 quarter results showing total revenue of $0.4M and a net loss of $4.7M, slightly improved from a $5.0M loss a year earlier. Cash and cash equivalents rose to $15.8M, helped by an initial private placement that raised roughly $15.9M and warrant exercises.
Total assets increased to $21.2M, with stockholders’ equity expanding to $16.0M. However, the company has an accumulated deficit of $137.0M and expects to continue incurring operating losses as it advances laromestrocel, its lead regenerative medicine candidate, through clinical development.
Management expects existing cash, including private placement proceeds, to fund operations into the fourth quarter of 2026, but its forecast shows insufficient cash to cover minimum commitments for 12 months. As a result, Longeveron discloses substantial doubt about its ability to continue as a going concern and indicates it must secure additional financing or revise its operating plan.
Longeveron Inc. reported outcomes of a recent Type C meeting with the U.S. FDA on its Phase 2b ELPIS II trial of laromestrocel (LOMECEL-B) for hypoplastic left heart syndrome (HLHS). The FDA stated that the trial’s current primary endpoint, right ventricle ejection fraction (RVEF), is not appropriate to demonstrate efficacy and, without an agreed primary endpoint, no longer refers to ELPIS II as a pivotal study.
The FDA highlighted objective measures such as all-cause mortality, cardiac transplant-free survival, cardiac transplantation events and major adverse cardiac events as more informative, and Longeveron is collecting these in ELPIS II. The company plans to submit a Sponsor Statistical Analysis Plan with a composite primary endpoint and secondary endpoints for FDA review, ahead of anticipated top-line ELPIS II results in August 2026 and a potential future Biologics License Application.
Lehr Paul T reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. reported that General Counsel and Secretary Paul T. Lehr received an equity grant of 250,000 shares of Class A common stock as a time-based vesting Restricted Stock Unit (RSU) award. The filing notes that Lehr’s holdings, including RSUs subject to future vesting, total 588,566 shares after this grant.
Willard Stephen H reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. Chief Executive Officer Willard Stephen H received an equity compensation award of 500,000 shares of Class A Common Stock on May 1, 2026. The award is structured as time-based vesting Restricted Stock Units (RSUs) granted at a stated price of $0.00 per share, so it is not an open-market purchase.
Following this grant, his directly held position in Longeveron Class A Common Stock is reported as 789,727 shares, which includes RSUs that are still subject to future vesting conditions.
Longeveron Inc. reported that CTO & SVP of CMC Devin Blass acquired 250,000 shares of Class A Common Stock on a grant/award basis. The shares were awarded as time-based vesting Restricted Stock Units, and total direct holdings increased to 441,543 shares, including RSUs subject to future vesting.
Longeveron Inc. reported that Chief Medical Officer Nataliya Agafonova acquired 250,000 shares of its Class A Common Stock through an award of time-based vesting Restricted Stock Units (RSUs) on May 1, 2026 at a stated price of $0.00 per share.
After this RSU award, she directly holds 453,419 Class A shares, which include RSUs subject to future vesting. The award reflects a non-cash equity grant classified as a grant, award, or other acquisition under insider reporting rules.
Locklear Lisa reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. Chief Financial Officer Lisa Locklear received an award of 250,000 shares of Class A Common Stock as time-based vesting Restricted Stock Units (RSUs). The grant was recorded at $0.00 per share, reflecting a compensation award rather than an open-market purchase.
After this award, Locklear directly holds 465,686 shares of Class A Common Stock, which the footnotes state includes RSUs that are still subject to future vesting conditions.
Longeveron Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on July 1, 2026. Key items include election of three Class II directors, a proposed increase in authorized Class A shares from 84,295,000 to 175,000,000, a possible reverse stock split in the range 1-for-2 to 1-for-20, and an amendment to expand the 2021 Incentive Award Plan.
The record date for voting is May 11, 2026, and the proxy materials, including the Annual Report for the year ended December 31, 2025, are available online at the meeting portal.
Longeveron Inc. registered 30,865,385 shares of Class A common stock for resale by certain selling stockholders. The prospectus covers (i) 6,013,384 issued shares, (ii) 22,832,770 shares issuable on conversion of Series A preferred stock, and (iii) up to 2,019,231 shares issuable on exercise of placement agent warrants.
The company will not receive proceeds from these resales, except for up to $1,312,500 if the PA Warrants are exercised for cash. Shares outstanding prior to the Private Placement were 21,783,749; fully converted/exercised outstanding would be 52,649,134 as disclosed. The registration satisfies contractual registration rights and permits the listed selling stockholders to sell shares on-market or in private transactions.